Safety Study of MGA271 in Refractory Cancer
Prostate Cancer - Melanoma - Renal Cell Carcinoma - Triple-negative Breast Cancer - Head and Neck Cancer - Bladder Cancer - Non-small Cell Lung Cancer
Conditions: official terms
Carcinoma, Non-Small-Cell Lung - Carcinoma, Renal Cell - Head and Neck Neoplasms - Prostatic Neoplasms - Triple Negative Breast Neoplasms - Urinary Bladder Neoplasms
Conditions: Keywords
Prostate cancer, Melanoma, Renal cell carcinoma, Triple-negative breast cancer, Head and neck cancer, Bladder cancer, Non-small cell lung cancer, Squamous cell carcinoma
Study Type
Study Phase
Phase 1
Study Design
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Name: MGA271
Type: Biological
Overall Status
The purpose of this study is to evaluate the safety of MGA271 when given by intravenous (IV) infusion to patients with refractory cancer. The study will also evaluate how long MGA271 stays in the blood and how long it takes for it to leave the body, what is the highest dose that can safely be given, and whether it may have an effect on tumors.
Detailed Description
An open-label, multi-dose, single-arm, multi-center, Phase 1, dose-escalation study will be conducted to define the toxicity profile, maximum tolerated dose (MTD), pharmacokinetics (PK), immunogenicity, and potential antitumor activity of MGA271 in patients with refractory cancer that expresses B7-H3.

In the initial segments of the study, patients will be monitored for a minimum of four weeks after administration of the final dose of MGA271. Study assessments will include adverse event (AE) monitoring, electrocardiogram (ECG) monitoring, PK analysis of serum MGA271, determination of the serum concentration of soluble MGA271 and tumor markers, and an assessment of potential anti-MGA271 antibody [human anti-human antibody (HAHA)] response.

Tumor response assessments using Study Day 43 CT scans or MRI will be performed approximately six weeks after the first MGA271 dose for each patient. Patients with evidence of clinical benefit (partial or complete response or stable disease by RECIST or RANO Response criteria) will be allowed to continue therapy at the same dose, or at a reduced dose if warranted by dose limiting toxicity (DLT) or significant AE in Cycle 1. Subsequent cycles which will begin on Study Day 50 will consist of MGA271 administration on Study Days 1, 8, and 15 of each 28-day cycle, with tumor evaluation every other cycle. Responding patients may receive continued antibody therapy until evidence of progression of disease is documented or the patient experiences DLT.

In the Expansion Segment of the study, patients will receive weekly, uninterrupted infusions with an initial response assessment at 8 weeks. Tumor evaluation will be carried out by both RECIST and immune-related response criteria (irRC).
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Histologically or cytologically confirmed carcinoma (prostate cancer, renal cell carcinoma, head and neck cancer, triple-negative breast cancer, bladder cancer, non-small cell lung cancer) or melanoma that overexpresses B7-H3.

- Progressive disease during or after last treatment regimen.

- Appropriate treatment history for histological entity.

- ECOG Performance Status <= 1.

- Life expectancy >= 3 months.

- Measurable disease or evaluable disease with relevant tumor marker elevation.

- Acceptable laboratory parameters and adequate organ reserve.

Exclusion Criteria:

- Major surgery or trauma within four weeks before enrollment.

- Known hypersensitivity to murine or recombinant proteins, polysorbate 80, or any excipient contained in the drug formulation.

- Grade 3 colitis, hepatitis, pneumonitis uveitis, myocarditis, myositis, CNS toxicity or autoimmune related neuromuscular toxicity such as myasthenia gravis associated with the administration of an immune checkpoint inhibitor

- Second primary malignancy that has not been in remission for greater than 3 years. Treated non-melanoma skin cancer, cervical carcinoma in situ on biopsy, or squamous intraepithelial lesion on PAP smear, localized prostate cancer (Gleason score < 6), or resected melanoma in situ are exceptions and do not require a 3 year remission.

- Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within four weeks of enrollment. Patients requiring any oral antiviral, fungal, or bacterial therapy must have completed treatment within one week of enrollment.

- Vaccination within 2 weeks of enrollment (except for annual flu vaccine).

- History of chronic or recurrent infections that require continual use of antiviral, antifungal, or antibacterial agents.
UCLA Hematology-Oncology Clinic
Los Angeles, California, United States
Status: Recruiting
Contact: Christine Kivork - 310-794-2464
Moffitt Cancer Center
Tampa, Florida, United States
Status: Recruiting
Contact: Allison Richards, MS - 813-745-8352 -
The University of Chicago
Chicago, Illinois, United States
Status: Recruiting
Contact: Katie McKeough, MA - 773-702-9136
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Status: Recruiting
Contact: Andrew Wolanski, NP - 617-632-6623
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
Status: Recruiting
Contact: Keith T. Flaherty, M.D. - 617-724-4800
Carolina Biooncology Institute
Huntersville, North Carolina, United States
Status: Recruiting
Contact: Dhiren Patel - 704-947-6599 -
Hospital of the University of Pennsylvania/Abramson Cancer Center
Philadelphia, Pennsylvania, United States
Status: Recruiting
Contact: Maryann Redlinger, RN - 215-662-7452 -
Sarah Cannon Research Institute
Nashville, Tennessee, United States
Status: Recruiting
Contact: Nurse Referral Line - 615-339-4214
Start Date
July 2011
Completion Date
February 2016
Record processing date processed this data on July 28, 2015 page